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Abstract Adenosine, a purine nucleoside and a ‘‘retalia-
tory metabolite’’ in ischemia, is ubiquitous in the body and
increases 100-fold during ischemia. Its biological actions are
mediated by four adenosine receptors (ARs): A1, A2A, A2B
and A3. The aim of this study was to determine possible
myocardial alterations in AR expression in an experimental
animal model of myocardial infarction (MI) with a preserved
left ventricular (LV) ejection fraction. LV tissue was col-
lected from sexually mature male farm pigs with MI (n = 6)
induced by permanent surgical ligation of the left anterior
descending coronary artery and from five healthy pigs (C).
mRNA expression of A1R, A2AR, A2BR, A3R and TNF-a
was determined by real-time PCR in tissue collected from
border (BZ) and remote zones (RZ) of the infarcted area and
from LV of C. BZ, RZ and samples of C were stained
immunohistochemically to investigate A3R immunoreac-
tion. After 4 weeks a different regulation of ARs was
observed. A1R mRNA expression was significantly lower in
the infarct regions than in controls (C = 0.75 ± 0.2,
BZ = 0.05 ± 0.2, RZ = 0.07 ± 0.02 p = 0.0025, p =
0.0016, C vs. BZ and RZ, respectively). Conversely A3R was
higher in infarct areas (C = 0.94 ± 0.2, BZ = 2.85 ± 0.5,
RZ = 3.48 ± 1.0, p = 0.048 C vs. RZ). No significant
differences were observed for A2AR (C = 1.58 ± 0.6,
BZ = 0.42 ± 0.1, RZ = 1.37 ± 0.6) and A2BR (C =
1.66 ± 0.2, BZ = 1.54 ± 0.5, RZ = 1.25 ± 0.4). A3R
expression was confirmed by immunohistochemical analysis
and was principally localized in cardiomyocytes. TNF-a
mRNA results were: C 0.41 ± 0.25; BZ 1.60 ± 0.19; RZ
0.17 ± 0.04. The balance between A1R and A3R as well as
between A2AR and A2BR was consistent with adaptative
retaliatory anti-ischemic adenosinergic changes in the
infarcted heart with preserved LV function.
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Introduction
Infarcted left ventricle with preserved ejection fraction
(EF) is a clinically relevant disease [1]. After an acute
myocardial infarction (MI) the magnitude of left ventric-
ular (LV) remodeling and the extent of scarring are key
predictors of cardiac performance and long-term prognosis
[2]. However, in infarcted hearts with preserved LV
function, the processes that underlie myocardial remod-
eling are likely multifactorial and still poorly defined [3–
5] although coronary revascularization plays the major
role [6].
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Biological and mechanical stressors such as ischemia,
hypoxia, cellular ATP depletion, free radicals, pressure and
volume overload, catecholamines and cytokines burst, and
the renin-angiotensin axis activation may independently
and simultaneously lead to different degrees of LV dys-
function after acute and severe coronary flow limitation.
Several endogenous self-protective mechanisms naturally
occurring to counteract LV remodeling fail in part to pre-
vent or limit cellular injury.
Adenosine, the catabolite of ATP, acts as an endogenous
cardioprotectant in different cardiovascular diseases, such
as MI and congestive heart failure [7, 8].
To the best of our knowledge, it is mainly released from
the cardiac cells when the myocardial oxygen supply is too
low, i.e., during ischemia, hypoxia or enhanced oxygen
consumption [9]. In fact, the adenosine extracellular con-
centration in body fluid may increase 100-fold under long-
standing ischemia [10].
Even though adenosine can directly enter into the
cardiomyocytes and promote ATP resynthesis in support of
cell functions, its physiological actions are mainly medi-
ated through the binding of selective receptors, which are
classified into three subtypes [11].
Adenosine A1 receptors (A1R) are responsible for the
inhibition of adenylate cyclase via activation of Gi pro-
teins; A2 receptors (A2AR, A2BR) are responsible for
stimulation of adenylate cyclase via activation of Gs pro-
teins, and A3 receptor (A3R) activation is thought to
increase phospholipase C activity via Go or Gq proteins
[11–13]. Since A1R and A3R are mainly distributed on
myocardial cells, and A2Rs are located on coronary vas-
cular smooth muscle cells, adenosine may substantially
modulate cardiac function as a whole [8, 14]. Although the
single role of each adenosine receptor in the heart is not
fully understood, the signaling that underlies the myocar-
dial adaptation to ischemic insult seems to be related to the
cross talk among several types of adenosine receptors
located on different cardiac cells.
The effects of A1R and probably of A3R appear to be
associated with actions on the myocyte, whereas the effects
of A2R seem to be related to vasodilation and actions on
cells in the vascular compartment [15].
In sum, A1R activation results in reduced O2 require-
ments, increased energy supply and decreased Ca2?
overload [15]. A3R activation may be involved in cardio-
protection seen as early preconditioning and is probably
mediated during ischemia although the mechanisms
involved are uncertain; A2Rs are mainly involved in the
vasodilating and antiplugging effects of adenosine, which
are particularly important during reperfusion.
A recent study has shown that AR subtypes may affect
the magnitude of fibrosis [16]. For example, adenosine
binding to A2BR inhibits collagenase production without
affecting either stromelysin or tissue inhibitor of metallo-
protease expression [17]. Thus, it is conceivable that
adenosine may play a critical role in collagen synthesis
and/or accumulation into the myocardium in the absence of
hemodynamic factors.
The aim of this study was to map the local changes of
myocardial AR expression in infarcted swine hearts with
preserved LVEF. Our experimental model is consistent
with the clinical condition of small LV infarct scar size
(\15 % transmurality), which does not affect the global
cardiac function (further parameters of in vivo hemody-
namic alterations of this model were reported in our pre-
vious studies [18, 19]) (Table 1).
Methods
Study design and tissue collection
All animals received human cure, and the study protocols
comply with the institution’s guidelines.
This protocol was approved by the Italian Ministry of
Health and was in accordance with Italian law (DL-116, 27
January 1992), which conforms to the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH publication no. 85-23,
revised 1996).
Fourteen healthy male sexually mature farm pigs
(35–40 kg) were surgically instrumented in the Laboratory
of Experimental Cardiology of Scuola Superiore Sant’Anna,
Pisa, Italy, as previously described [18, 19]. They were
randomized in two experimental groups: (1) MI (n = 9), (2)
sham-operated animals (control, C: n = 5). Three MI ani-
mals died because of ventricular fibrillation after ligation of
the left anterior descending (LAD) coronary artery. Four
weeks after surgery, the cardiac performance of sedated
Table 1 Cardiac MRI measurements
Normal Myocardial
infarction
Heart rate (beats/min) 90 ± 5.77 89.60 ± 8.2
Mean aortic pressure (mmHg) 118.33 ± 10.7 124.43 ± 11.5
ES volume (ml) 21.71 ± 5.5 24 ± 1.7
ED volume (ml) 60.86 ± 4.2 65.5 ± 4.5
Cardiac output (l/min) 4.62 ± 0.3 4.72 ± 0.4
Stroke volume (ml) 39.15 ± 1.34 41.5 ± 3.2
Ejection fraction (%) 64.32 ± 6.85 63 ± 1.5
End-systolic wall-thickening
border zone (%)
64.16 ± 9.69 8.4 ± 16.6*
End-systolic wall-thickening
remote zone (%)
68.45 ± 12.5 62 ± 9.3
* p \ 0.05
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animals was investigated by magnetic resonance imaging
(1.5 T, Signa Excite HD; GE Medical Systems, Waukesha,
WI) as reported earlier [18, 19].
Anesthetized pigs were killed by infusion of a cold
cardioplegia solution to collect cardiac tissue for molecular
and histological analysis [18, 19]. LV tissue samples were
quickly harvested from the infarct border (BZ) and non-
infarcted remote zones (RZ) of the MI group, and from
healthy LV wall of the C group, and were immediately
placed in ice-cold RNAlater and stored at -80 C.
Molecular analysis
RNA extraction
Total RNA was extracted by the acid guanidinium thio-
cyanate-phenol-chloroform method from LV tissue sam-
ples obtained from pig hearts with the Rneasy Midi kit
(Qiagen S.p.A, Milano, Italy) as previously described [19–
25]. The RNA samples were stored at -80 C for sub-
sequent gene expression studies.
Real-time PCR
Following DNAse treatment, first strand cDNA was syn-
thesized with iScript cDNA Synthesis kit (Bio-rad, Her-
cules, CA, USA) using about 1 lg of total RNA as
template. Real-time PCR was conducted on a 96-well iQ
Cycler Real-time PCR detection system (Bio-rad, Hercules,
CA, USA) in a 25-ll final volume, using 12.5 ll of iQ
SYBR Green Supermix 2X (Bio-rad, Hercules, CA, USA)
and 2 ll of cDNA as template. Annealing temperatures
vary depending on the primer pair used (Table 2).
A series of PCRs were performed using primer pairs for
A1R, A2AR, A2BR, A3R and TNF-a. Primer pairs were
designed with Primer Express version 2.0 (Applied Bio-
systems), and details are given in Table 2. Specificity of
each primer pair, i.e., absence of artifacts, multiple PCR
products or primer dimers, and PCR yields were checked
by agarose-gel electrophoresis and by melting analysis. All
reactions were performed in duplicate.
Immunohistochemistry analysis
Five-lm-thick sections of LV tissue samples from infarct
BZ, RZ and healthy myocardium were used for immuno-
histochemical analysis as previously described [19].
A3R expression was detected using a rabbit anti-human
adenosine A3R antibody (ADORA3, MBL International
Corp., MA, USA) diluted 1:100 in BSA-PBS. This anti-
body reacts with pig A3R on paraffined sections as speci-
fied by the supplier. For each selected specimen, at least
three serial sections 1/10 were examined using a semi-
quantitative scale of immunoreactivity: no (-), low (?)
and high (??) staining. Negative controls, obtained by
incubating the specimens with BSA-PBS, omitting the
primary antibody, were performed to test the specificity of
the secondary biotinilated antibody. Representative pho-
tomicrographs were taken by a DFC480 digital camera
(Leica Microsystem, Cambridge, UK).
Table 2 Primers pairs
Primer pair used for
housekeeping and target genes
in real-time qPCR experiments
A1R adenosine: A1 receptor,
A2AR adenosine: A2A receptor,
A2BR adenosine: A2B receptor,
A3R adenosine: A3 receptor,
TNF-a: tumor necrosis factor-a,
GAPDH: glyceraldehyde
3-phosphate dehydrogenase,
CypA: cyclophilin A, TBP:
TATA-Binding protein, ACTB:
beta-actin
Gene Primers Annealing T GeneBank
A1R 5
0-ATCAGGTTACTTGGTTCT-30 57 AY772411
50-ATCAGGTTACTTGGTTCT-30
A2AR 5
0-GATCAGCCTCCGCCTCAACGGCCA-30 60.5 AY772412
50-TCAGGACACTCCTGCTCTGTCCTG-30
A2BR 5
0-TGGTGTACTTCAACTTCCTG-30 60 AY772413
50-GATCTTGGCGTAGATGGC-30
A3R 5
0-GGTGAAGTGCCAGAAGTTGTG-30 60 AY772414
50-AGCATAGACGATAGGGTTCATCAT-30
TNF-a 50-TGACCACCACCAAGAATT-30 60 NM_214022
50-TGTTCTGAAGTATTCCGATTG-30
GAPDH 50-TCGGAGTGAACGGATTTG-30 59 AF017079
50-CCTGGAAGATGGTGATGG-30
CypA 50-GGGTGGTGACTTCACACGCCA-30 60 AY266299
50-TTGGGAACCGTTTGTGTTGGGGC-30
TBP 50-GATGGACGTTCGGTTTAGG-30 59 DQ178129
50-AGCAGCACAGTACGAGCAA-30
ACTB 50-TCTGGCACCACACCTTCT-30 60 DQ178122
50-TGATCTGGGTCATCTTCTCAC-30
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Data analysis and statistics
Several reference genes were tested, and GeNorm software
was used to define the most stably expressed gene set, as
previously described [26, 27]. The geometric mean of the
four most stably expressed genes (CYC, TBP, ACTB,
GAPDH) was used for normalization of each gene mRNA
expression in the samples [19]. The relative quantification
was performed by the DDCt method using the iQ5 Soft-
ware (BioRad). Differences between more than two inde-
pendent groups were analyzed by Fisher’s test after
ANOVA. The results are expressed as mean ± SEM, and
p values were considered significant when \0.05.
Results
We analyzed LV myocardial tissue samples from the left
ventricle with infarct scar size corresponding to 13 ± 1 % of
the LV wall mass, as shown in our previous studies [18, 19].
Four weeks after acute LAD ligation, we observed a
different LV regulation of AR expression (Fig. 1). A1R
mRNA expression was significantly lower in the BZ than
in controls. Conversely, A3R was higher in both BZ and
RZ. No significant changes were observed at the level of
A2AR and A2BR receptors in each LV sample. A significant
correlation (r = 0.55, p = 0.04) was observed between
A2AR and A2BR mRNA level. A3R expression in cardio-
myocytes was detected by immunohistochemical analysis
that showed low immunostaining (?) for all C samples and
strong immunoreaction (???) for all BZ and RZ samples
(Fig. 2). A3R expression was almost undetectable in
endothelial cells (Fig. 2 squares).
The TNF-a mRNA myocardial level tended to be higher
in the LV infarct BZ compared to RZ and normal myo-
cardium (Fig. 3), yet no statistically significant differences
were detected.
Discussion
The main result of this study was that the myocardial
expression of all AR subtypes is differently modulated in
distinct regions of infarcted swine left ventricle in the
absence of hemodynamic factors, but not in healthy
myocardium.
Fig. 1 a A1R, b A2AR, c A2BR and d A3R mRNA expression measured by real-time PCR in the control (white bars), border zone (BZ) (grey
bars) and remote zone (black bars)
Heart Vessels
123
A transcriptional balance between A1R and A3R as well
as A2AR and A2BR was observed, consistent with an
adaptative retaliatory anti-ischemic adenosinergic mecha-
nism after myocardial infarction even in the presence of a
globally preserved LV function.
Our findings suggest that adenosine is a paracrine
mediator of post-ischemic myocardial remodeling inde-
pendent of mechanical stress.
The present study was partly in accordance with the
fascinating hypothesis of Von Lubitz [28] that supports the
existence of a concentration gradient of adenosine sur-
rounding the ischemic infarct area. The ischemic ‘‘core’’ is
characterized by diffuse necrosis and consequent massive
formation of adenosine from catabolism of nucleic acids. It
is conceivable that the extracellular concentrations of
adenosine following myocardial necrosis are sufficient to
induce a sustained regulation of the specific receptor
apparatus of cardiomyocytes, in particular the A3R recep-
tors. Once the A3Rs have been upregulated, they attenuate
the inhibitory feedback on glutamate release by A1R,
resulting in further release of the neurotransmitter, hence in
an enhancement of cell damage [29, 30].
The high adenosine concentrations could induce a
desensitization of A1R, which may explain the very low
levels of mRNA expression observed for this receptor
subtype in BZ and RZ as also suggested by a previous
study in which a desensitization and internalization of A1R
were observed during periods of ischemia [31–33]. A1R
belong to the G protein-coupled receptor family but, unlike
most in their family, A1Rs have a long half-life [33] and
seem to be resilient to desensitization [34]. In light of the
evidence, A3R seems to play a key role in the paracrine
myocardial response during the ischemic remodeling pro-
cess, yet its mechanism is still not well defined [35]. In this
study the upregulated transcription of A3R was also con-
firmed by immunohistochemical analysis where increased
expression of A3R in the infarct BZ and RZ compared to
normal myocardial tissue from sham-operated animals was
detected.
Since a similar and stable A3R mRNA and protein
expression was found in both LV regions, we further
confirmed that the adenosinergic response of ischemic
cardiomyocytes is modulated at the transcriptional level.
However, these data are more controversial in the presence
of significant deposits of collagen in the BZ region, which
are absent in the RZ [18, 19]. We suggest that the local
release of adenosine following MI causes an epigenetic
domino effect on A3R expression in series of cardiomyo-
cytes, but the role is still to be proven.
The role of two A2 subtypes under ischemic conditions
is poorly understood, but is emerging as modulators of
cardiovascular stress responses and inflammatory pro-
cesses. Since both A2 subtypes possess immunomodulatory
and anti-inflammatory functions, they thus may well reg-
ulate the impact of inflammatory processes on ischemic
and postischemic damage [36]. It has been speculated that
under pathologic conditions, such as ischemia, A2BR may
be upregulated to compensate for the downregulation of
A2AR-mediated responses [37]. In particular, A2BR
Fig. 2 A3R
immunohistochemical
expression in the control (C),
border zone (BZ) and remote
zone (brown color). Negative
control was obtained omitting
the primary antibody. Arrows
indicate endothelial cells
Fig. 3 TNF-a mRNA expression measured by real-time PCR in
cardiac tissue of the control (white bars), border zone (BZ) (grey
bars) and remote zone (black bars)
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upregulation has been detected in ischemic mouse hearts
and in A1R knockout animals [38, 39].
In this study, adenosine concentrations were not mea-
sured since this molecule is rapidly degraded into inosine,
making its assessment technically very difficult, hence the
physiological relevance of AR expression as an indirect
marker of adenosine release.
The main limitation of the study is the lack of phar-
macological approaches by adenosine agonists/antagonists
to better comprehend the role of adenosine receptors in
regulating myocardial infarction. However, data provided
by this experimental model are valuable as a starting point
for new studies focused on understanding and defining
possible new pharmacological approaches in the setting of
acute myocardial infarction in clinical practice.
Adenosine is one of the most intriguing cardioprotective
molecules; data based on extensive literature on adenos-
inergic protection led Kitakaze et al. [8] to conclude in a
recent paper: ‘‘we have asked what does stress to the heart
do for adenosine, so now it is time to ask what adenosine
can do for patients with heart disease.’’
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